Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

PHAT stock hub

Phathom Pharmaceuticals, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

PHATis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

965.9M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

PHAT

In the news

Latest news · PHAT

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E33.4

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROIC-27.7

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All PHAT market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

206

Groups with data

Currency

USD

Showing 206 of 206 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001783183
Company name	Phathom Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	71722W107
Employees	371
Employees Change	-56%
Employees Change Percent	-13.11
Enterprise value	$1.3B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2019-10-25
Isin	US71722W1071
Last refreshed	2026-05-10
Market cap	$965.9M
Market cap category	Small-Cap
Price	$12.16
Price currency	USD
Rev Per Employee	552,269.54x
Sector	Healthcare
Sic	2834
Symbol	PHAT
Website	https://www.phathompharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-16.29%
EV Sales Forward	3.44x
EV/Sales	6.5x
FCF yield	-10.12%
Forward P/E	33.41x
P/S ratio	4.71x
PS Forward	2.49x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-47.15%
EBITDA Margin	-46.87%
Gross margin	84.93%
Gross Profit	$174M
Gross Profit Growth	146.53%
Gross Profit Growth Q	86.75%
Net Income	$-157.3M
Net Income Growth Quarters	4%
Net Income Growth Years	1%
Pretax Margin	-76.77%
Profit Margin	-76.77%
Profit Per Employee	$-423,989
ROA	-20.15
Roa5y	-41.4
ROCE	-53.64
ROIC	-27.66

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	407.23%
Cagr3y	-0.52%
Cagr5y	-19.04%
EPS Growth Quarters	6
EPS Growth Years	1
Revenue Growth	150.3x
Revenue Growth Q	104.43x
Revenue Growth Quarters	6x
Revenue Growth Years	2x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.68
Assets	$305.1M
Cash	$180.9M
Current Assets	$276.6M
Current Liabilities	$125M
Debt	$547.2M
Equity	$-337M
Interest Coverage	-1.47
Liabilities	$642.1M
Long Term Assets	$28.5M
Long Term Liabilities	$517M
Net Cash	$-366.3M
Net Cash By Market Cap	$-37.93
Tangible Book Value	$-337M
Tangible Book Value Per Share	$-4.24
WACC	8.14

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.21
Inventory Turnover	6.38
Net Working Capital	$4.3M
Quick ratio	2.09
Working Capital	$151.5M
Working Capital Turnover	$1.2

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-13.31%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	406.67%
200-day SMA	12.67
3Y total return	-1.54%
50-day SMA	11.58
50-day SMA vs 200-day SMA	50under200
5Y total return	-65.22%
All Time High	64.54
All Time High Change	-81.16%
All Time High Date	2020-06-08
All Time Low	2.21
All Time Low Change	450.23%
All Time Low Date	2025-05-08
ATR	0.87
Beta	0.57
Beta1y	2.66
Beta2y	2.01
Ch YTD	-26.7
High	12.39
High52	18.31
High52 Date	2025-12-23
High52ch	-33.59%
Low	11.93
Low52	2.21
Low52 Date	2025-05-08
Low52ch	450.23%
Ma50ch	5.03%
Premarket Change Percent	0.16
Premarket Price	$12.25
Premarket Volume	1,609
Price vs 200-day SMA	-4.05%
RSI	50.95
RSI Monthly	51.11
RSI Weekly	49.13
Sharpe ratio	1.8x
Sortino ratio	5.06
Total Return	-13.31%
Tr YTD	-26.7
Tr1m	5.28%
Tr1w	1.25%
Tr3m	-3.34%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	6
Analyst Count Top	4
Analyst Price Target Top	$24
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.21
Earnings Revenue Estimate	56,792,264x
Earnings Revenue Estimate Growth	99.14x
Operating Income	$-96.6M
Operating margin	-47.15
Price target	$19.83
Price Target Change	$63.08
Price Target Change Top	$97.37

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	60,032,127%
Float Percent	75.58%
Net Borrowing	-55,797,000
Shares Insiders	3.44%
Shares Institutions	51.6%
Shares Out	79,430,098
Shares Qo Q	11.15%
Shares Yo Y	13.31%
Short Float	15.83%
Short Ratio	8.77
Short Shares	11.96

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-126.5M
Average Volume	1,418,294.5x
Bv Per Share	-4.24
CAPEX	$-272,000
Ch1m	5.28
Ch1w	1.25
Ch1y	406.7
Ch3m	-3.34
Ch3y	-1.54
Ch5y	-65.22
Ch6m	-8.23
Change	-0.57%
Change From Open	-0.9
Close	12.23
Days Gap	0.33
Depreciation Amortization	566,000
Dollar Volume	7,647,448.3
Earnings Date	2026-04-30
Earnings Time	bmo
EBIT	$-96.6M
EBITDA	$-96M
EPS	$-2.09
F Score	3
FCF	$-97.8M
FCF EV Yield	-7.34x
FCF Per Share	$-1.23
Financing CF	66,352,000
Fiscal Year End	December
Founded	2,018
Investing CF	-272,000
Ipr	-36
Iprfo	-45.96
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-04-30
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-26
Ma150	13.26
Ma150ch	-8.3%
Ma20	12.32
Ma20ch	-1.26%
Net CF	-31,412,000
Next Earnings Date	2026-08-06
Open	12.27
Optionable	Yes
Position In Range	50
Post Close	12.16
Postmarket Change Percent	-1.89
Postmarket Price	$11.93
Ppne	3,524,000
Pre Close	12.23
Price Date	2026-05-08
Relative Volume	0.44x
Revenue	204,892,000x
SBC By Revenue	14.01x
Share Based Comp	28,713,000
Tr6m	-8.23%
Us State	New Jersey
Volume	628,902
Z Score	-6

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does PHAT pay a dividend?

Capital-return profile for this ticker.

Performance

PHAT stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns PHAT?

Insider, institutional, and short-interest positioning.

Institutional ownership

+51.6%

Float: +75.6% of shares outstanding

Insider ownership

+3.4%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

PHAT momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

51.0

Neutral momentum band

Price vs 200-day MA

-4.0%

50/200-day relationship not available

Beta (5Y)

0.57

Less volatile than the market

Sharpe ratio

1.80

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About PHAT

Hub-level FAQ points readers to the deeper analysis pages.

What is the current PHAT stock rating?

Phathom Pharmaceuticals, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full PHAT analysis?

The full report lives at /stocks/PHAT/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for PHAT?

The latest report frames PHAT around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the PHAT page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.